Table I.
Comparison of baseline characteristics, laboratory and pathological findings across groups of patients with low and high NMPVR values
| Parameter | NMPVR | ||
|---|---|---|---|
| Low (< 0.41) (n = 172) | High (≥ 0.41) (n = 172) | P-value | |
| Sex: | 0.08 | ||
| Male | 46% | 55% | |
| Female | 54% | 45% | |
| Age [years] | 64.0 (55.0–71.0) | 62.0 (54.0–69.0) | 0.2 |
| BMI [kg/m2] | 27.2 (24.5–30.7) | 27.1 (24.6–30.2) | 0.82 |
| Hemoglobin [g/dl] | 13.7 (12.8–14.7) | 13.9 (12.4–15.1) | 0.71 |
| Red blood cell count [× 106/mm3] | 4.47 (4.25–4.77) | 4.61 (4.29–4.9) | 0.11 |
| White blood cell count [× 106/mm3] | 5.6 (5.0–6.4) | 8.0 (6.8–9.1) | < 0.0001 |
| Lymphocytes [× 103/mm3] | 1.9 (1.5–2.4) | 1.9 (1.6–2.5) | 0.26 |
| Neutrophils [× 103/mm3] | 3.1 (2.5–3.6) | 5.0 (4.1–5.9) | < 0.0001 |
| Monocytes [× 103/mm3] | 0.4 (0.3–0.5) | 0.5 (0.4–0.6) | < 0.0001 |
| Platelets [× 103/mm3] | 219.0 (175.0–260.0) | 267.0 (220.0–330.0) | < 0.0001 |
| MPV [fl] | 10.4 (9.0–11.8) | 8.5 (7.7–9.8) | < 0.0001 |
| Sarcomatoid feature: | 0.39 | ||
| Present | 1% | 2% | |
| Absent | 99% | 98% | |
| pT stage: | 0.009 | ||
| pT1/pT2 | 84% | 72% | |
| pT3/pT4 | 16% | 28% | |
| Lymph node involvement: | 0.54 | ||
| pN0 | 97% | 96% | |
| pN1 | 3% | 4% | |
| TNM stage: | 0.003 | ||
| I | 73% | 55% | |
| II | 10% | 15% | |
| III | 17% | 29% | |
| IV | 0% | 1% | |
| Tumor grade: | 0.005 | ||
| G1/G2 | 77% | 63% | |
| G3/G4 | 23% | 37% | |
| Tumor size [mm] | 45.0 (35.0–60.0) | 60.0 (40.0–75.0) | 0.001 |
| Nephrectomy: | 0.04 | ||
| Partial | 39% | 28% | |
| Radical | 61% | 72% | |
| Tumor necrosis: | 0.04 | ||
| Present | 11% | 19% | |
| Absent | 89% | 81% | |
| Overall survival | 68% | 58% | 0.002* |
| Cancer-specific survival | 86% | 77% | 0.006* |
*
log-rank. Continuous variables are presented as median (interquartile range). Dichotomous variables are presented as percentages. BMI – body mass index, MPV – mean platelet volume, NMPVR – neutrophil-to-mean platelet volume ratio.